Innovative Immunotherapy Consortium Aims to Match Patients with Effective Treatments
Eindhoven, Wednesday, 12 March 2025.
The RESIGHT consortium, spearheaded by TU Eindhoven, focuses on leveraging molecular imaging to enhance immunotherapy by aligning treatments with patient-specific needs, backed by €18 million funding.
Advancing Personalized Immunotherapy
The newly formed FORESIGHT consortium, led by researchers from multiple Dutch institutions including TU Eindhoven, aims to revolutionize immunotherapy treatment through advanced molecular imaging techniques. With funding of €3 million per year from Health~Holland, matched by private sector contributions for a total of €18 million over the 2025-2027 period [1][3], the initiative brings together expertise from UMC Groningen, Amsterdam UMC, NKI/AVL, and Eindhoven University of Technology [1].
Technology and Innovation Focus
The consortium’s primary challenge lies in matching patients with appropriate immunotherapy treatments. As TU/e researcher Fons van der Sommen explains, ‘Thanks to these very advanced imaging techniques that will be investigated within FORESIGHT, we have insights we can use to train AI models’ [1]. The initiative will establish a specialized program focusing on tracer development, bioengineering, imaging, and data analysis for various conditions including oncological, autoimmune, cardiovascular, and neurodegenerative diseases [3].
Leadership and Expertise
The consortium is guided by a team of distinguished researchers, including Liesbeth de Vries of UMC Groningen, Guus van Dongen from Amsterdam UMC, John Haanen of NKI/AVL, and Peter de With from TU/e [3]. The Department of Biomedical Engineering at TU Eindhoven brings substantial expertise in biomedical imaging and modeling, operating at the intersection of engineering, biology, and medicine [4].
Future Impact and Implementation
The first call for research proposals is expected in early 2025 [3], with the consortium’s work building upon TU Eindhoven’s established strengths in chemical biology, regenerative engineering, and biomedical imaging [4]. The initiative represents a significant step forward in personalizing immunotherapy treatments, with potential applications across multiple medical disciplines [1][3].